Pfizer (NYSE:PFE) Trading Up 2%

Pfizer Inc. (NYSE:PFE) shares were up 2% during trading on Wednesday . The company traded as high as $29.18 and last traded at $29.13. Approximately 8,421,879 shares changed hands during trading, a decline of 80% from the average daily volume of 42,146,465 shares. The stock had previously closed at $28.56.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Trading Up 2.5 %

The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $165.86 billion, a P/E ratio of -485.42, a PEG ratio of 1.20 and a beta of 0.63. The business has a 50 day moving average of $27.22 and a 200-day moving average of $27.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 EPS. Analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.74%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Institutional Investors Weigh In On Pfizer

A number of large investors have recently added to or reduced their stakes in the business. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter worth approximately $30,000. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer in the fourth quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.